-
Kenya's economy faces climate change risks: World Bank
-
Qantas to launch non-stop Sydney-London flights in October 2027
-
US Fed chair Warsh vows reforms as central bank signals rate hikes on horizon
-
US Federal Reserve holds rates steady, raises inflation expectations
-
Brest boss Roy dies aged 58 from cancer
-
Military salutes and K-pop madness shake up Colombia campaigning
-
Recovery of ship traffic in Hormuz limited, but signs emerge
-
England's World Cup opener puts Spanish resort on beer alert
-
Nations allege 'attacks' on science at key climate talks
-
Plague was killing hunter-gatherers 5,500 years ago: study
-
Prince Harry and family to visit UK in July: media
-
What happens when the Strait of Hormuz re-opens?
-
US retail sales beat expectations in May as energy costs stay high
-
Spain logs third-warmest year on record in 2025
-
'Heartbreaking': Afghan govt staff abandon smartphones
-
Groundbreaking US astronaut Christina Koch wins top Spanish award
-
BBC eyes compulsory redundancies in cost-cutting drive
-
Sovereignty fears dog AI enthusiasm at France's Vivatech
-
Japan puts the heat on suspected ice cream cartel
-
Sovereignty fears to dog AI enthusiasm at France's Vivatech
-
MEXC May Report: SPACEX Launchpad Oversubscribed 15.5x, US Equity Futures Volume Jumps 85%
-
MEXC Prediction Markets Launches Combo to Enable Multi-Event Combination Trading
-
'We have always won': Ebola pioneer still on front line at 84
-
Trap, neuter, release: Jakarta battles cat-astrophic stray numbers
-
US Fed set to hold rates steady at Warsh's first meeting in charge
-
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA
-
Spanish actor Javier Bardem leaves his mark on Hollywood Boulevard
-
After three sessions, SpaceX already among world's most valuable companies
-
Surging SpaceX overtakes Amazon to become 5th biggest company
-
BMW downgrades 2026 targets on Mideast war, China woes
-
German court bans McDonald's from making climate claim
-
Campaigners urge G7 chiefs to protect children from AI risks
-
Like father, like son: Prince George to attend Eton College
-
Paris store to part ways with Shein after ownership change
-
US Federal Reserve kicks off first meeting with Warsh as chair
-
How can France-UK mission help reopen Strait of Hormuz?
-
EU to ban plant-based 'steaks' but veggie 'burgers' sizzle on
-
Russian oil producer rations fuel as Ukraine attacks bite
-
EU clears major hurdle on US tariff deal
-
Mideast war peace deal boosts German investor morale
-
Iran says talks on final US deal to begin this week
-
With feasts and music, Kashmiri weddings keep traditions alive
-
French spies drop AI giant Palantir over US overreliance fears
-
India blocks Telegram before retest exam to curb cheating
-
Bank of Japan hikes interest rate to 31-year high
-
Stocks extend rally, oil flat as peace optimism builds
-
Deadline looms for UniCredit's hostile bid for Commerzbank
-
Bank of Japan hikes rate to 31-year high
-
Scientist confronting the rising global threat of mosquitoes
-
India eyes biofertilisers after Mideast war stoked supply fears
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.K.Baumgartner--CPN